Sana Biotechnology Inc. (NASDAQ: SANA) stock jumped 8.61% on Friday to $4.54 against a previous-day closing price of $4.18. With 1.23 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.02 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.6150 whereas the lowest price it dropped to was $4.1500. The 52-week range on SANA shows that it touched its highest point at $9.92 and its lowest point at $3.15 during that stretch. It currently has a 1-year price target of $9.75.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SANA was down-trending over the past week, with a drop of -0.66%, but this was up by 32.75% over a month. Three-month performance dropped to -12.52% while six-month performance fell -49.50%. The stock lost -50.44% in the past year, while it has gained 14.94% so far this year. A look at the trailing 12-month EPS for SANA yields -1.61 with Next year EPS estimates of -2.10. For the next quarter, that number is -0.52. This implies an EPS growth rate of -37.80% for this year and -17.30% for next year.
Float and Shares Shorts:
At present, 189.30 million SANA shares are outstanding with a float of 169.28 million shares on hand for trading. On Oct 13, 2022, short shares totaled 25.27 million, which was 13.29% higher than short shares on Sep 14, 2022. In addition to Dr. Steven D. Harr M.D. as the firm’s Pres, CEO & Director, Dr. Richard C. Mulligan Ph.D. serves as its Exec. Vice Chairman & Head of SanaX.
Through their ownership of 88.56% of SANA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 32.87% of SANA, in contrast to 27.96% held by mutual funds. Shares owned by individuals account for 15.09%. As the largest shareholder in SANA with 5.64% of the stake, Baillie Gifford & Co. holds 10,764,727 shares worth 10,764,727. A second-largest stockholder of SANA, Canada Pension Plan Investment Bo, holds 10,175,000 shares, controlling over 5.34% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in SANA, holding 8,703,138 shares or 4.56% stake. With a 5.34% stake in SANA, the Canada Pension Plan is the largest stakeholder. A total of 10,175,000 shares are owned by the mutual fund manager. The Scottish Mortgage Investment Trus, which owns about 2.93% of SANA stock, is the second-largest Mutual Fund holder. It holds 5,586,264 shares valued at 22.07 million. SPDR S&P Biotech ETF holds 2.63% of the stake in SANA, owning 5,023,269 shares worth 19.84 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SANA since 4 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SANA analysts setting a high price target of $15.00 and a low target of $5.00, the average target price over the next 12 months is $9.75. Based on these targets, SANA could surge 230.4% to reach the target high and rise by 10.13% to reach the target low. Reaching the average price target will result in a growth of 114.76% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. SANA will report FY 2022 earnings on 03/13/2024. Analysts have provided yearly estimates in a range of -$1.52 being high and -$2.30 being low. For SANA, this leads to a yearly average estimate of -$1.79. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Sana Biotechnology Inc. surprised analysts by $0.00 when it reported -$0.48 EPS against a consensus estimate of -$0.48. The surprise factor in the prior quarter was $0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.41 and the low estimate is -$0.52. The average estimate for the next quarter is thus -$0.48.
Summary of Insider Activity:
Insiders traded SANA stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 9 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 107,016 while 333 shares were sold.